Thyrocare Tech. Q1 FY27 Results (NSE: THYROCARE)

23 Jul 2026 · Analysis by Alpha Inflection

Signal: Growth reaccelerated

The read

Thyrocare delivered solid top-line growth (24% YoY) driven by volume (28% test growth) and network expansion. EBITDA margin improved to ~34%, reflecting operating leverage. However, EPS shows a sharp decline (-56%) contradictory to PAT growth, raising data quality concerns. Strategic expansion into specialty diagnostics (allergy, genomics) is a positive. Overall operating performance remains strong, but the EPS anomaly needs resolution.

P&L walk

Consolidated revenue grew 24.3% YoY to ₹240.02 Cr, driven by 28% test volume growth and 26% pathology revenue increase. EBITDA grew 30.4% YoY to ₹81.42 Cr, with margin expanding to 33.9% (prior year ~32%) on volume-led operating leverage and quality efficiencies. PAT rose 34.1% to ₹52.19 Cr, but EPS basic declined 56.1% to ₹3.23, an anomaly requiring investigation.

Segments

Pathology segment is the sole revenue driver, growing 26% YoY with franchise and partnership revenue up 27% and 26% respectively. No other segments disclosed.

Key positives

• Revenue up 24% YoY to ₹240 Cr, driven by 28% test volume growth – volume leadership reinforced
• EBITDA grew 30% YoY to ₹81.42 Cr, margin at 33.9% – operating leverage evident
• Pathology segment up 26%, franchise revenue +27%, partnership +26% – network scaling well
• Expansion into specialty diagnostics (allergy, genomics) opens new growth frontier
• Quality metrics improved: complaints per million down 24% to 3.1, ATAT 3.37 hours – Six Sigma benchmark

Key concerns

• EPS basic declined 56.1% YoY despite PAT growth of 34.1% – data integrity or dilution issue
• Sequential revenue comparison not provided; XBRL QoQ of -71% appears erroneous but not clarified
• No update on franchisee net additions or specific FY27 guidance; open claims remain unresolved

View original filing

Research and educational content only. Not investment advice.